Her primary areas of study are Myeloid leukemia, Leukemia, Cancer research, Internal medicine and Oncology. Her Myeloid leukemia research integrates issues from Karyotype, Bioinformatics, Immunophenotyping, Cytogenetics and Bone marrow. Her Leukemia research includes elements of Myeloid, Gene, Chromosomal translocation and Neuroblastoma RAS viral oncogene homolog.
Her Cancer research research is multidisciplinary, incorporating elements of Mutation, Fms-Like Tyrosine Kinase 3, Gene expression profiling, Molecular biology and NPM1. Her work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Pathology. Her Oncology study combines topics from a wide range of disciplines, such as Proportional hazards model, Immunology and Transplantation.
Susanne Schnittger mainly investigates Leukemia, Internal medicine, Myeloid leukemia, Oncology and Immunology. Her work deals with themes such as Myeloid, Molecular biology, NPM1 and Cytogenetics, which intersect with Leukemia. Her research investigates the connection between Cytogenetics and topics such as Fluorescence in situ hybridization that intersect with issues in Chronic lymphocytic leukemia.
Her Internal medicine research incorporates elements of Gastroenterology, Karyotype and Pathology. Her Myeloid leukemia study results in a more complete grasp of Cancer research. Her Oncology study incorporates themes from Transplantation, Bioinformatics, Proportional hazards model, Imatinib and Cohort.
Susanne Schnittger mainly investigates Internal medicine, Leukemia, Oncology, Immunology and Myeloid leukemia. Her Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Karyotype. The Leukemia study combines topics in areas such as Myeloid, KRAS, NPM1, Cytogenetics and ETV6.
The concepts of her Oncology study are interwoven with issues in Trisomy, Gene mutation, Neuroblastoma RAS viral oncogene homolog, Chromosome abnormality and Acute leukemia. She combines subjects such as Young adult, Survival rate and Somatic evolution in cancer with her study of Immunology. She interconnects Gene duplication, Fms-Like Tyrosine Kinase 3 and Philadelphia chromosome in the investigation of issues within Myeloid leukemia.
Susanne Schnittger mostly deals with Internal medicine, Mutation, Myeloid leukemia, Genetics and Myeloid. Her Internal medicine study combines topics in areas such as Oncology and RUNX1. Her research in Mutation intersects with topics in Molecular biology and NPM1.
Her Myeloid leukemia study improves the overall literature in Immunology. Her research integrates issues of Essential thrombocythemia, Polycythemia vera and Disease in her study of Genetics. Myeloid is a subfield of Cancer research that she tackles.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Susanne Schnittger;Claudia Schoch;Martin Dugas;Wolfgang Kern.
Dominant-negative mutations of CEBPA , encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
Thomas Pabst;Beatrice U. Mueller;Pu Zhang;Hanna S. Radomska.
Nature Genetics (2001)
BRAF mutations in hairy-cell leukemia
Enrico Tiacci;Vladimir Trifonov;Gianluca Schiavoni;Antony Holmes.
The New England Journal of Medicine (2011)
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
Susanne Schnittger;Claudia Schoch;Wolfgang Kern;Cristina Mecucci.
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
Ramiro Garzon;Michela Garofalo;Maria Paola Martelli;Roger Briesewitz.
Proceedings of the National Academy of Sciences of the United States of America (2008)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniel Cilloni;Aline Renneville;Fabienne Hermitte;Robert Kerrin Hills.
Journal of Clinical Oncology (2009)
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
Susanne Schnittger;Tobias M. Kohl;Torsten Haferlach;Wolfgang Kern.
Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes
Yasunobu Nagata;Vera Grossmann;Yusuke Okuno;Ulrike Bacher.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
B. Hanfstein;M. C. Müller;R. Hehlmann;P. Erben.
New insights to the MLL recombinome of acute leukemias
C. Meyer;E. Kowarz;J. Hofmann;A. Renneville.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: